Effect of alpha-1 antitrypsin and alpha-1-acid glycoprotein levels on prognosis in patients with COPD exacerbation and COPD-community-acquired pneumonia

Abstract

Aims: Chronic obstructive pulmonary disease (COPD) is the most frequent comorbid condition that is present in patients with pneumonia. An exacerbations of chronic obstructive pulmonary disease (ECOPD) and Comminity-acquired pneumonia (CAP) are associated with high rates of hospitalizations, costs, and morbidity. Plasma levels of orosomucoid and Alpha-1 antitrypsin (AAT), also known as Alpha-1-acid glycoprotein (AGP), increase in response to inflammation and tissue necrosis. The purpose of this study is to evaluate the impact of markers in patients with ECOPD and COPD with pneumonia . Methods: To compare the levels of AAT, and AGP, between patients diagnosed with ECOPD only and patients diagnosed with COPD and pneumonia. Results: The study included 14 female and 22 male volunteers. The mean gender and age of groups 1 and 2 were similar. There was no statistical difference in laboratory values between the groups. Conclusion: Alpha-1-acid glycoprotein and AAT are acute-phase proteins elevated in various inflammatory conditions such as infections, trauma, and chronic diseases such as COPD. More studies are needed on their usefulness for monitoring and/or treatment in daily practice.